Cargando…

Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicentre cohort of HIV-infected, ARV-naïve patients

PURPOSE: Very scarce information has been published to date with the combination of ABC/3TC/NVP but it is currently being used in clinical practice in Spain and Portugal. Our aim was to present the clinical experience with this regimen in a cohort of adult HIV-infected antiretroviral (ARV)-naïve pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Podzamczer, Daniel, Fredy Rojas, Jhon, Neves, Isabel, Ferrer, Elena, Llibre, Josep M, Leal, Manuel, Gorgolas, Miguel, Jose, Crusells M, Gatell, Josep M, Correia Abreu, Ricardo, Curto, Jordi, Domingo, Pere, Pilar, Barrufet M, Rozas, Nerea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P241
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225404/ https://www.ncbi.nlm.nih.gov/pubmed/25397517 http://dx.doi.org/10.7448/IAS.17.4.19773

Ejemplares similares

Impact de l’obésité sur l’évolution de la pneumopathie COVID-19
por: Kalboussi, S., et al.
Publicado: (2022)

Outcomes Following Lvad Implantation In Covid-19 Patients
por: Zakrzewski, Jack, et al.
Publicado: (2022)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study
por: de Boissieu, Paul, et al.
Publicado: (2016)

Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
por: Martínez, E, et al.
Publicado: (2010)

Long-term fat redistribution in ARV-naïve HIV+ patients initiating a non-thymidine containing regimen in clinical practice
por: Ferrer, Elena, et al.
Publicado: (2014)

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine
por: Rogatto, Felipe, et al.
Publicado: (2014)

Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia
por: Llibre, Josep M., et al.
Publicado: (2015)

An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: M. Llibre, Josep, et al.
Publicado: (2016)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
por: Llibre, Josep M., et al.
Publicado: (2016)

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
por: Troya, Jesús, et al.
Publicado: (2016)

Environmental Risk Characterization of an Antiretroviral (ARV) Lamivudine in Ecosystems
por: Omotola, Elizabeth Oyinkansola, et al.
Publicado: (2021)

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study
por: Llibre, Josep M., et al.
Publicado: (2016)

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study
por: Troya, Jesús, et al.
Publicado: (2017)

Abacavir/lamivudine combination in the treatment of HIV: a review
por: Sivasubramanian, Geetha, et al.
Publicado: (2010)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
por: Janneh, Omar, et al.
Publicado: (2011)

Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA)
Publicado: (2008)

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study
por: Troya, Jesús, et al.
Publicado: (2018)

Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan†
por: Kurita, Tomoko, et al.
Publicado: (2014)

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)
por: Podzamczer, D, et al.
Publicado: (2021)

Tolerance and durability of abacavir/lamivudine (ABC/3TC)-containing regimens: results from a large prospective French cohort
por: Cuzin, L, et al.
Publicado: (2010)

Combination dolutegravir–abacavir–lamivudine in the management of HIV/AIDS: clinical utility and patient considerations
por: Cruciani, Mario, et al.
Publicado: (2015)

Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
por: Olalla, Julián, et al.
Publicado: (2018)

Abacavir/dolutegravir/lamivudine: Delayed hepatotoxicity and drug-induced liver injury: case report
Publicado: (2021)

A Korean Post-Marketing Study of Abacavir/Dolutegravir/Lamivudine in Patients with HIV-1
por: Shin, Sang-Kyu, et al.
Publicado: (2023)

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults
por: Gatell, Josép M, et al.
Publicado: (2014)

Switching to nevirapine (NVP) significantly increases high-density lipoprotein cholesterol (HDL-C) in treatment-experienced patients (NEVICOR study)
por: Rodriguez, JM, et al.
Publicado: (2010)

Randomized Trial Evaluating the Neurotoxicity of Dolutegravir/Abacavir/Lamivudine and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: GESIDA 9016
por: Perez Valero, Ignacio, et al.
Publicado: (2020)

Sex differences in apolipoprotein A1 and nevirapine-induced toxicity
por: Marinho, Aline, et al.
Publicado: (2014)

Intrinsic Replication Competences of HIV Strains After Zidovudine/Lamivudine/Nevirapine Treatment in the Philippines
por: Kageyama, Seiji, et al.
Publicado: (2019)

Brain antioxidants and hippocampal microanatomical alterations following the administration of Efavirenz/Lamivudine/Tenofovir disoproxil fumarate and Lamivudine/Nevirapine/Zidovudine in adult male Wistar rats
por: Edagha, Innocent A., et al.
Publicado: (2022)

Correction to: efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks
por: Olalla, Julián, et al.
Publicado: (2023)

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
por: Wolf, E, et al.
Publicado: (2010)

Safety and Effectiveness Analysis of Kivexa(®) (lamivudine/abacavir sulfate) in Human Immunodeficiency Virus Infected Korean Patients
por: Ann, Heawon, et al.
Publicado: (2019)

Abacavir/Dolutegravir/Lamivudine (Triumeq)–Induced Liver Toxicity in a Human Immunodeficiency Virus–Infected Patient
por: Christensen, Erin S., et al.
Publicado: (2017)

Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children
por: Bunupuradah, Torsak, et al.
Publicado: (2015)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-Infected Ugandan Adults
por: Byakika-Tusiime, Jayne, et al.
Publicado: (2008)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_nkvi2m88hflpiopfkiq112iulj